Aleksandra Podlecka-Piętowska, Janusz Sierdziński, Monika Nojszewska, Jakub Stawicki, Halina Bartosik-Psujek, Beata Lech, Małgorzata Popiel, Adam Perenc, Alina Kułakowska, Agata Czarnowska, Joanna Kulikowska, Katarzyna Kapica-Topczewska, Anna Jamróz-Wiśniewska, Konrad Rejdak, Jacek Zaborski, Katarzyna Kubicka-Bączyk, Natalia Niedziela, Krzysztof Wierzbicki, Monika Adamczyk-Sowa, Jacek Zwiernik, Beata Zwiernik, Marta Milewska-Jędrzejczak, Andrzej Głąbiński, Elżbieta Jasińska, Przemysław Puz, Ewa Krzystanek, Arkadiusz Stęposz, Aleksandra Karuga, Anetta Lasek-Bal, Joanna Siuda, Barbara Kściuk, Anna Walawska-Hrycek, Maja Patalong-Ogiewa, Aleksandra Kaczmarczyk, Katarzyna Siutka, Waldemar Brola, Beata Zakrzewska-Pniewska
CLINICAL RATIONALE FOR THE STUDY: The rapid spread of SARS-CoV-2 throughout the world has highlighted the importance of vaccinations to control the pandemic and to protect people at risk for severe disease courses. Disease-modifying therapies (DMT) in multiple sclerosis (MS), whether immunomodulatory or immunosuppressive, may affect the immune response. Therefore, the question arose as to whether these vaccinations would be effective. AIM OF THE STUDY: We planned a study to assess the immune response to SARS-CoV-2 vaccines by type of therapy...
January 22, 2024: Neurologia i Neurochirurgia Polska